CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing

113
11
Favorite

CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing

investorplace2021-06-30

Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

113

Report

Comment（11）

TimTamPrata
·2021-06-30
[Happy]
Reply
4
Report
Fold Replies
- Long2themoon:
  HuaT
  2021-06-30
  Reply
  Report
- ShirlySuet:
  ?
  2021-06-30
  Reply
  Report
Buythedip
·2021-06-30
Wow
Reply
2
Report
patrickLai
·2021-06-30
Yes
Reply
Like
Report
Slee49
·2021-06-30
Like
Reply
9
Report
Fold Replies
- ericteh859:
  ok
  2023-03-31
  Reply
  Report
- Weeareus:
  comment
  2021-06-30
  Reply
  Report
- mebugsbunny:
  Like
  2021-06-30
  Reply
  Report
View more 2 comments
KH321
·2021-06-30
Will benefit those who can afford to pay
Reply
6
Report
Fold Replies
- US_watchlist:
  great
  2021-06-30
  Reply
  Report
Catherine321
·2021-06-30
Yes
Reply
5
Report
Cubercubic
·2021-06-30
To the moon?
Reply
3
Report
Bonds
·2021-06-30
Hope the rest will be the same
Reply
4
Report
Catherine321
·2021-06-30
Wow
Reply
2
Report
HongBoonPing
·2021-06-30
Ok great
Reply
1
Report
StanWong
·2021-06-30
Nice
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1114123601?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-30 10:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114123601","market":"us","top_or_hot":-1,"title":"CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing","media":"investorplace","content":"<div>\n<p>Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of ...</p>\n\n<a href=\"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/\">Source Link</a>\n\n</div>\n","source":"lsy1606302653667","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of ...</p>\n\n<a href=\"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CERE","symbol_name":"Cerevel Therapeutics Holdings, Inc.","start_time":0,"source_url":"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/","article_id":"1114123601","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114123601","pubTimestamp":1625021346,"sourceInfo":{"source_id":"lsy1606302653667","name":"InvestorPlace"},"weMediaInfo":null,"summary":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a bre","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CERE":"Cerevel Therapeutics Holdings, Inc."},"translate_title":"Cerevel疗法暴涨的大新闻","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CERE":0.9},"content_text":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing the start of the next phase, a hopeful sign for getting it to market. Investors are taking notice of the 125% gain for CERE stock.\nCambridge-based Cerevel Therapeutics has been tackling schizophrenia treatment recently, and its newest trial results are showing that it is heading in the right direction. The results come from the testing of the company’sCVL-231 antipsychoticdrug.\nThe CVL-231 treatment seeks to reduce the release of dopamine in patients without directly targeting dopamine receptors. It does this by manipulating the activation of M4 receptors in the brain.\nOver a six-week trial period, subjects were administered either a once- or twice-daily dosage of CVL-231, or a placebo. At the end of the trial, the company noticed a statistically significant reduction of “psychotic activity” in the subjects taking CVL-231 as compared to those taking the placebo.\nAlso of note is the optimistic information regarding side effects. According to the company’s press release, the drug was well tolerated. Side effects, including headaches and heart rate and blood pressure increases, were relatively stable between both those taking CVL-231 and those taking the placebo.\nCERE Stock Sees Gigantic Gains After Posting Trial Results\nThe results of this trial are very positive for the company. Chief Scientific Officer of Cerevel, Dr. John Renger, commented on the results, reaffirming the company’s belief that it is on the right track:\n\n “We are extremely encouraged with these results, which we believe support our hypothesis that a targeted muscarinic therapy that is highly selective for M4 receptors could deliver clinically meaningful benefit in the treatment of schizophrenia.”\n\nThe next step, according to the company, is moving the drug into more robust trials.\nAs a result of the positive press release, CERE stock is flying high today. In fact, the stock is more than doubling in value, rocketing nearly 125% on today’s trading session. Trading volume is up far above the average; over 76 million shares of CERE stock are swapping hands, against the 300,000 daily average.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":153229358,"gmtCreate":1625028552474,"gmtModify":1703850493718,"author":{"id":"3581478820646520","authorId":"3581478820646520","name":"TimTamPrata","avatar":"https://static.tigerbbs.com/7112dd358a087dca78af99b862816363","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581478820646520","authorIdStr":"3581478820646520"},"htmlText":"[Happy]&nbsp;","listText":"[Happy]&nbsp;","text":"[Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/153229358","repostId":1114123601,"repostType":4,"repost":{"id":"1114123601","pubTimestamp":1625021346,"share":"https://ttm.financial/m/news/1114123601?lang=&edition=fundamental","pubTime":"2021-06-30 10:49","market":"us","language":"en","title":"CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing","url":"https://stock-news.laohu8.com/highlight/detail?id=1114123601","media":"investorplace","summary":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a bre","content":"<p><b>Cerevel Therapeutics</b>(NASDAQ:<b><u>CERE</u></b>) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing the start of the next phase, a hopeful sign for getting it to market. Investors are taking notice of the 125% gain for CERE stock.</p>\n<p>Cambridge-based Cerevel Therapeutics has been tackling schizophrenia treatment recently, and its newest trial results are showing that it is heading in the right direction. The results come from the testing of the company’sCVL-231 antipsychoticdrug.</p>\n<p>The CVL-231 treatment seeks to reduce the release of dopamine in patients without directly targeting dopamine receptors. It does this by manipulating the activation of M4 receptors in the brain.</p>\n<p>Over a six-week trial period, subjects were administered either a once- or twice-daily dosage of CVL-231, or a placebo. At the end of the trial, the company noticed a statistically significant reduction of “psychotic activity” in the subjects taking CVL-231 as compared to those taking the placebo.</p>\n<p>Also of note is the optimistic information regarding side effects. According to the company’s press release, the drug was well tolerated. Side effects, including headaches and heart rate and blood pressure increases, were relatively stable between both those taking CVL-231 and those taking the placebo.</p>\n<p>CERE Stock Sees Gigantic Gains After Posting Trial Results</p>\n<p>The results of this trial are very positive for the company. Chief Scientific Officer of Cerevel, Dr. John Renger, commented on the results, reaffirming the company’s belief that it is on the right track:</p>\n<blockquote>\n “We are extremely encouraged with these results, which we believe support our hypothesis that a targeted muscarinic therapy that is highly selective for M4 receptors could deliver clinically meaningful benefit in the treatment of schizophrenia.”\n</blockquote>\n<p>The next step, according to the company, is moving the drug into more robust trials.</p>\n<p>As a result of the positive press release, CERE stock is flying high today. In fact, the stock is more than doubling in value, rocketing nearly 125% on today’s trading session. Trading volume is up far above the average; over 76 million shares of CERE stock are swapping hands, against the 300,000 daily average.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of ...</p>\n\n<a href=\"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CERE":"Cerevel Therapeutics Holdings, Inc."},"source_url":"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114123601","content_text":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing the start of the next phase, a hopeful sign for getting it to market. Investors are taking notice of the 125% gain for CERE stock.\nCambridge-based Cerevel Therapeutics has been tackling schizophrenia treatment recently, and its newest trial results are showing that it is heading in the right direction. The results come from the testing of the company’sCVL-231 antipsychoticdrug.\nThe CVL-231 treatment seeks to reduce the release of dopamine in patients without directly targeting dopamine receptors. It does this by manipulating the activation of M4 receptors in the brain.\nOver a six-week trial period, subjects were administered either a once- or twice-daily dosage of CVL-231, or a placebo. At the end of the trial, the company noticed a statistically significant reduction of “psychotic activity” in the subjects taking CVL-231 as compared to those taking the placebo.\nAlso of note is the optimistic information regarding side effects. According to the company’s press release, the drug was well tolerated. Side effects, including headaches and heart rate and blood pressure increases, were relatively stable between both those taking CVL-231 and those taking the placebo.\nCERE Stock Sees Gigantic Gains After Posting Trial Results\nThe results of this trial are very positive for the company. Chief Scientific Officer of Cerevel, Dr. John Renger, commented on the results, reaffirming the company’s belief that it is on the right track:\n\n “We are extremely encouraged with these results, which we believe support our hypothesis that a targeted muscarinic therapy that is highly selective for M4 receptors could deliver clinically meaningful benefit in the treatment of schizophrenia.”\n\nThe next step, according to the company, is moving the drug into more robust trials.\nAs a result of the positive press release, CERE stock is flying high today. In fact, the stock is more than doubling in value, rocketing nearly 125% on today’s trading session. Trading volume is up far above the average; over 76 million shares of CERE stock are swapping hands, against the 300,000 daily average.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5078238,"gmtCreate":1625036182063,"gmtModify":1663230326031,"authorId":3581627460874168,"author":{"id":3581627460874168,"idStr":"3581627460874168","authorId":3581627460874168,"name":"Long2themoon","avatar":"https://static.tigerbbs.com/b6efd17f4feb4272fc08d9033b1d5b82","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153229358,"type":1,"supId":0,"prevId":0,"content":"HuaT","text":"HuaT","html":"HuaT"},{"id":5077460,"gmtCreate":1625028798624,"gmtModify":1663230320434,"authorId":3582360052677778,"author":{"id":3582360052677778,"idStr":"3582360052677778","authorId":3582360052677778,"name":"ShirlySuet","avatar":"https://static.tigerbbs.com/57d93e0a20280806b45e744b5e2a11cb","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153229358,"type":1,"supId":0,"prevId":0,"content":"?","text":"?","html":"?"}],"langContent":"EN"},{"id":153237089,"gmtCreate":1625026644041,"gmtModify":1703850446828,"author":{"id":"3573375517846152","authorId":"3573375517846152","name":"Buythedip","avatar":"https://community-static.tradeup.com/news/e7905324638a15789f7ab478cba611c9","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3573375517846152","authorIdStr":"3573375517846152"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153237089","repostId":1114123601,"repostType":4,"repost":{"id":"1114123601","pubTimestamp":1625021346,"share":"https://ttm.financial/m/news/1114123601?lang=&edition=fundamental","pubTime":"2021-06-30 10:49","market":"us","language":"en","title":"CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing","url":"https://stock-news.laohu8.com/highlight/detail?id=1114123601","media":"investorplace","summary":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a bre","content":"<p><b>Cerevel Therapeutics</b>(NASDAQ:<b><u>CERE</u></b>) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing the start of the next phase, a hopeful sign for getting it to market. Investors are taking notice of the 125% gain for CERE stock.</p>\n<p>Cambridge-based Cerevel Therapeutics has been tackling schizophrenia treatment recently, and its newest trial results are showing that it is heading in the right direction. The results come from the testing of the company’sCVL-231 antipsychoticdrug.</p>\n<p>The CVL-231 treatment seeks to reduce the release of dopamine in patients without directly targeting dopamine receptors. It does this by manipulating the activation of M4 receptors in the brain.</p>\n<p>Over a six-week trial period, subjects were administered either a once- or twice-daily dosage of CVL-231, or a placebo. At the end of the trial, the company noticed a statistically significant reduction of “psychotic activity” in the subjects taking CVL-231 as compared to those taking the placebo.</p>\n<p>Also of note is the optimistic information regarding side effects. According to the company’s press release, the drug was well tolerated. Side effects, including headaches and heart rate and blood pressure increases, were relatively stable between both those taking CVL-231 and those taking the placebo.</p>\n<p>CERE Stock Sees Gigantic Gains After Posting Trial Results</p>\n<p>The results of this trial are very positive for the company. Chief Scientific Officer of Cerevel, Dr. John Renger, commented on the results, reaffirming the company’s belief that it is on the right track:</p>\n<blockquote>\n “We are extremely encouraged with these results, which we believe support our hypothesis that a targeted muscarinic therapy that is highly selective for M4 receptors could deliver clinically meaningful benefit in the treatment of schizophrenia.”\n</blockquote>\n<p>The next step, according to the company, is moving the drug into more robust trials.</p>\n<p>As a result of the positive press release, CERE stock is flying high today. In fact, the stock is more than doubling in value, rocketing nearly 125% on today’s trading session. Trading volume is up far above the average; over 76 million shares of CERE stock are swapping hands, against the 300,000 daily average.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of ...</p>\n\n<a href=\"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CERE":"Cerevel Therapeutics Holdings, Inc."},"source_url":"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114123601","content_text":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing the start of the next phase, a hopeful sign for getting it to market. Investors are taking notice of the 125% gain for CERE stock.\nCambridge-based Cerevel Therapeutics has been tackling schizophrenia treatment recently, and its newest trial results are showing that it is heading in the right direction. The results come from the testing of the company’sCVL-231 antipsychoticdrug.\nThe CVL-231 treatment seeks to reduce the release of dopamine in patients without directly targeting dopamine receptors. It does this by manipulating the activation of M4 receptors in the brain.\nOver a six-week trial period, subjects were administered either a once- or twice-daily dosage of CVL-231, or a placebo. At the end of the trial, the company noticed a statistically significant reduction of “psychotic activity” in the subjects taking CVL-231 as compared to those taking the placebo.\nAlso of note is the optimistic information regarding side effects. According to the company’s press release, the drug was well tolerated. Side effects, including headaches and heart rate and blood pressure increases, were relatively stable between both those taking CVL-231 and those taking the placebo.\nCERE Stock Sees Gigantic Gains After Posting Trial Results\nThe results of this trial are very positive for the company. Chief Scientific Officer of Cerevel, Dr. John Renger, commented on the results, reaffirming the company’s belief that it is on the right track:\n\n “We are extremely encouraged with these results, which we believe support our hypothesis that a targeted muscarinic therapy that is highly selective for M4 receptors could deliver clinically meaningful benefit in the treatment of schizophrenia.”\n\nThe next step, according to the company, is moving the drug into more robust trials.\nAs a result of the positive press release, CERE stock is flying high today. In fact, the stock is more than doubling in value, rocketing nearly 125% on today’s trading session. Trading volume is up far above the average; over 76 million shares of CERE stock are swapping hands, against the 300,000 daily average.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153235842,"gmtCreate":1625026584186,"gmtModify":1703850444688,"author":{"id":"3585604372962377","authorId":"3585604372962377","name":"patrickLai","avatar":"https://static.tigerbbs.com/baedd77ad7c3a28da1ae2ecc8b2e88aa","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"3585604372962377","authorIdStr":"3585604372962377"},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153235842","repostId":1114123601,"repostType":4,"repost":{"id":"1114123601","pubTimestamp":1625021346,"share":"https://ttm.financial/m/news/1114123601?lang=&edition=fundamental","pubTime":"2021-06-30 10:49","market":"us","language":"en","title":"CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing","url":"https://stock-news.laohu8.com/highlight/detail?id=1114123601","media":"investorplace","summary":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a bre","content":"<p><b>Cerevel Therapeutics</b>(NASDAQ:<b><u>CERE</u></b>) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing the start of the next phase, a hopeful sign for getting it to market. Investors are taking notice of the 125% gain for CERE stock.</p>\n<p>Cambridge-based Cerevel Therapeutics has been tackling schizophrenia treatment recently, and its newest trial results are showing that it is heading in the right direction. The results come from the testing of the company’sCVL-231 antipsychoticdrug.</p>\n<p>The CVL-231 treatment seeks to reduce the release of dopamine in patients without directly targeting dopamine receptors. It does this by manipulating the activation of M4 receptors in the brain.</p>\n<p>Over a six-week trial period, subjects were administered either a once- or twice-daily dosage of CVL-231, or a placebo. At the end of the trial, the company noticed a statistically significant reduction of “psychotic activity” in the subjects taking CVL-231 as compared to those taking the placebo.</p>\n<p>Also of note is the optimistic information regarding side effects. According to the company’s press release, the drug was well tolerated. Side effects, including headaches and heart rate and blood pressure increases, were relatively stable between both those taking CVL-231 and those taking the placebo.</p>\n<p>CERE Stock Sees Gigantic Gains After Posting Trial Results</p>\n<p>The results of this trial are very positive for the company. Chief Scientific Officer of Cerevel, Dr. John Renger, commented on the results, reaffirming the company’s belief that it is on the right track:</p>\n<blockquote>\n “We are extremely encouraged with these results, which we believe support our hypothesis that a targeted muscarinic therapy that is highly selective for M4 receptors could deliver clinically meaningful benefit in the treatment of schizophrenia.”\n</blockquote>\n<p>The next step, according to the company, is moving the drug into more robust trials.</p>\n<p>As a result of the positive press release, CERE stock is flying high today. In fact, the stock is more than doubling in value, rocketing nearly 125% on today’s trading session. Trading volume is up far above the average; over 76 million shares of CERE stock are swapping hands, against the 300,000 daily average.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of ...</p>\n\n<a href=\"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CERE":"Cerevel Therapeutics Holdings, Inc."},"source_url":"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114123601","content_text":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing the start of the next phase, a hopeful sign for getting it to market. Investors are taking notice of the 125% gain for CERE stock.\nCambridge-based Cerevel Therapeutics has been tackling schizophrenia treatment recently, and its newest trial results are showing that it is heading in the right direction. The results come from the testing of the company’sCVL-231 antipsychoticdrug.\nThe CVL-231 treatment seeks to reduce the release of dopamine in patients without directly targeting dopamine receptors. It does this by manipulating the activation of M4 receptors in the brain.\nOver a six-week trial period, subjects were administered either a once- or twice-daily dosage of CVL-231, or a placebo. At the end of the trial, the company noticed a statistically significant reduction of “psychotic activity” in the subjects taking CVL-231 as compared to those taking the placebo.\nAlso of note is the optimistic information regarding side effects. According to the company’s press release, the drug was well tolerated. Side effects, including headaches and heart rate and blood pressure increases, were relatively stable between both those taking CVL-231 and those taking the placebo.\nCERE Stock Sees Gigantic Gains After Posting Trial Results\nThe results of this trial are very positive for the company. Chief Scientific Officer of Cerevel, Dr. John Renger, commented on the results, reaffirming the company’s belief that it is on the right track:\n\n “We are extremely encouraged with these results, which we believe support our hypothesis that a targeted muscarinic therapy that is highly selective for M4 receptors could deliver clinically meaningful benefit in the treatment of schizophrenia.”\n\nThe next step, according to the company, is moving the drug into more robust trials.\nAs a result of the positive press release, CERE stock is flying high today. In fact, the stock is more than doubling in value, rocketing nearly 125% on today’s trading session. Trading volume is up far above the average; over 76 million shares of CERE stock are swapping hands, against the 300,000 daily average.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153627436,"gmtCreate":1625023019625,"gmtModify":1703850361021,"author":{"id":"3581993357014262","authorId":"3581993357014262","name":"Slee49","avatar":"https://static.tigerbbs.com/a4a9c556617a3ec3446f5c1c667b4aa0","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":5,"crmLevelSwitch":1,"idStr":"3581993357014262","authorIdStr":"3581993357014262"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/153627436","repostId":1114123601,"repostType":4,"repost":{"id":"1114123601","pubTimestamp":1625021346,"share":"https://ttm.financial/m/news/1114123601?lang=&edition=fundamental","pubTime":"2021-06-30 10:49","market":"us","language":"en","title":"CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing","url":"https://stock-news.laohu8.com/highlight/detail?id=1114123601","media":"investorplace","summary":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a bre","content":"<p><b>Cerevel Therapeutics</b>(NASDAQ:<b><u>CERE</u></b>) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing the start of the next phase, a hopeful sign for getting it to market. Investors are taking notice of the 125% gain for CERE stock.</p>\n<p>Cambridge-based Cerevel Therapeutics has been tackling schizophrenia treatment recently, and its newest trial results are showing that it is heading in the right direction. The results come from the testing of the company’sCVL-231 antipsychoticdrug.</p>\n<p>The CVL-231 treatment seeks to reduce the release of dopamine in patients without directly targeting dopamine receptors. It does this by manipulating the activation of M4 receptors in the brain.</p>\n<p>Over a six-week trial period, subjects were administered either a once- or twice-daily dosage of CVL-231, or a placebo. At the end of the trial, the company noticed a statistically significant reduction of “psychotic activity” in the subjects taking CVL-231 as compared to those taking the placebo.</p>\n<p>Also of note is the optimistic information regarding side effects. According to the company’s press release, the drug was well tolerated. Side effects, including headaches and heart rate and blood pressure increases, were relatively stable between both those taking CVL-231 and those taking the placebo.</p>\n<p>CERE Stock Sees Gigantic Gains After Posting Trial Results</p>\n<p>The results of this trial are very positive for the company. Chief Scientific Officer of Cerevel, Dr. John Renger, commented on the results, reaffirming the company’s belief that it is on the right track:</p>\n<blockquote>\n “We are extremely encouraged with these results, which we believe support our hypothesis that a targeted muscarinic therapy that is highly selective for M4 receptors could deliver clinically meaningful benefit in the treatment of schizophrenia.”\n</blockquote>\n<p>The next step, according to the company, is moving the drug into more robust trials.</p>\n<p>As a result of the positive press release, CERE stock is flying high today. In fact, the stock is more than doubling in value, rocketing nearly 125% on today’s trading session. Trading volume is up far above the average; over 76 million shares of CERE stock are swapping hands, against the 300,000 daily average.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of ...</p>\n\n<a href=\"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CERE":"Cerevel Therapeutics Holdings, Inc."},"source_url":"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114123601","content_text":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing the start of the next phase, a hopeful sign for getting it to market. Investors are taking notice of the 125% gain for CERE stock.\nCambridge-based Cerevel Therapeutics has been tackling schizophrenia treatment recently, and its newest trial results are showing that it is heading in the right direction. The results come from the testing of the company’sCVL-231 antipsychoticdrug.\nThe CVL-231 treatment seeks to reduce the release of dopamine in patients without directly targeting dopamine receptors. It does this by manipulating the activation of M4 receptors in the brain.\nOver a six-week trial period, subjects were administered either a once- or twice-daily dosage of CVL-231, or a placebo. At the end of the trial, the company noticed a statistically significant reduction of “psychotic activity” in the subjects taking CVL-231 as compared to those taking the placebo.\nAlso of note is the optimistic information regarding side effects. According to the company’s press release, the drug was well tolerated. Side effects, including headaches and heart rate and blood pressure increases, were relatively stable between both those taking CVL-231 and those taking the placebo.\nCERE Stock Sees Gigantic Gains After Posting Trial Results\nThe results of this trial are very positive for the company. Chief Scientific Officer of Cerevel, Dr. John Renger, commented on the results, reaffirming the company’s belief that it is on the right track:\n\n “We are extremely encouraged with these results, which we believe support our hypothesis that a targeted muscarinic therapy that is highly selective for M4 receptors could deliver clinically meaningful benefit in the treatment of schizophrenia.”\n\nThe next step, according to the company, is moving the drug into more robust trials.\nAs a result of the positive press release, CERE stock is flying high today. In fact, the stock is more than doubling in value, rocketing nearly 125% on today’s trading session. Trading volume is up far above the average; over 76 million shares of CERE stock are swapping hands, against the 300,000 daily average.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":106181685,"gmtCreate":1680273972080,"gmtModify":1680273975381,"authorId":4101623900408000,"author":{"id":4101623900408000,"idStr":"4101623900408000","authorId":4101623900408000,"name":"ericteh859","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153627436,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"},{"id":5076771,"gmtCreate":1625023484361,"gmtModify":1663230321043,"authorId":3583964165805413,"author":{"id":3583964165805413,"idStr":"3583964165805413","authorId":3583964165805413,"name":"Weeareus","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153627436,"type":1,"supId":0,"prevId":0,"content":"comment","text":"comment","html":"comment"},{"id":5076730,"gmtCreate":1625023163353,"gmtModify":1663230320640,"authorId":3582002742425523,"author":{"id":3582002742425523,"idStr":"3582002742425523","authorId":3582002742425523,"name":"mebugsbunny","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153627436,"type":1,"supId":0,"prevId":0,"content":"Like","text":"Like","html":"Like"},{"id":5077128,"gmtCreate":1625026537272,"gmtModify":1663230320538,"authorId":3581640085724727,"author":{"id":3581640085724727,"idStr":"3581640085724727","authorId":3581640085724727,"name":"cryptous","avatar":"https://static.tigerbbs.com/c66c79b1c0f576bf4133fe7ceb3916ae","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153627436,"type":1,"supId":5076771,"prevId":0,"content":"<u>hehe</u>","text":"<u>hehe</u>","html":"<u>hehe</u>"},{"id":5076968,"gmtCreate":1625025267602,"gmtModify":1663230317842,"authorId":3577189579318003,"author":{"id":3577189579318003,"idStr":"3577189579318003","authorId":3577189579318003,"name":"Zhenghao","avatar":"https://static.tigerbbs.com/9bc02f1c85fb8e61dbc393ac0ad551db","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153627436,"type":1,"supId":0,"prevId":0,"content":"Nice","text":"Nice","html":"Nice"}],"langContent":"EN"},{"id":153668518,"gmtCreate":1625022168534,"gmtModify":1703850339022,"author":{"id":"3586451610703869","authorId":"3586451610703869","name":"KH321","avatar":"https://static.tigerbbs.com/c1bb8bd7d6d5df5f9732871fe60999ea","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586451610703869","authorIdStr":"3586451610703869"},"htmlText":"Will benefit those who can afford to pay&nbsp;","listText":"Will benefit those who can afford to pay&nbsp;","text":"Will benefit those who can afford to pay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/153668518","repostId":1114123601,"repostType":4,"repost":{"id":"1114123601","pubTimestamp":1625021346,"share":"https://ttm.financial/m/news/1114123601?lang=&edition=fundamental","pubTime":"2021-06-30 10:49","market":"us","language":"en","title":"CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing","url":"https://stock-news.laohu8.com/highlight/detail?id=1114123601","media":"investorplace","summary":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a bre","content":"<p><b>Cerevel Therapeutics</b>(NASDAQ:<b><u>CERE</u></b>) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing the start of the next phase, a hopeful sign for getting it to market. Investors are taking notice of the 125% gain for CERE stock.</p>\n<p>Cambridge-based Cerevel Therapeutics has been tackling schizophrenia treatment recently, and its newest trial results are showing that it is heading in the right direction. The results come from the testing of the company’sCVL-231 antipsychoticdrug.</p>\n<p>The CVL-231 treatment seeks to reduce the release of dopamine in patients without directly targeting dopamine receptors. It does this by manipulating the activation of M4 receptors in the brain.</p>\n<p>Over a six-week trial period, subjects were administered either a once- or twice-daily dosage of CVL-231, or a placebo. At the end of the trial, the company noticed a statistically significant reduction of “psychotic activity” in the subjects taking CVL-231 as compared to those taking the placebo.</p>\n<p>Also of note is the optimistic information regarding side effects. According to the company’s press release, the drug was well tolerated. Side effects, including headaches and heart rate and blood pressure increases, were relatively stable between both those taking CVL-231 and those taking the placebo.</p>\n<p>CERE Stock Sees Gigantic Gains After Posting Trial Results</p>\n<p>The results of this trial are very positive for the company. Chief Scientific Officer of Cerevel, Dr. John Renger, commented on the results, reaffirming the company’s belief that it is on the right track:</p>\n<blockquote>\n “We are extremely encouraged with these results, which we believe support our hypothesis that a targeted muscarinic therapy that is highly selective for M4 receptors could deliver clinically meaningful benefit in the treatment of schizophrenia.”\n</blockquote>\n<p>The next step, according to the company, is moving the drug into more robust trials.</p>\n<p>As a result of the positive press release, CERE stock is flying high today. In fact, the stock is more than doubling in value, rocketing nearly 125% on today’s trading session. Trading volume is up far above the average; over 76 million shares of CERE stock are swapping hands, against the 300,000 daily average.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of ...</p>\n\n<a href=\"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CERE":"Cerevel Therapeutics Holdings, Inc."},"source_url":"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114123601","content_text":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing the start of the next phase, a hopeful sign for getting it to market. Investors are taking notice of the 125% gain for CERE stock.\nCambridge-based Cerevel Therapeutics has been tackling schizophrenia treatment recently, and its newest trial results are showing that it is heading in the right direction. The results come from the testing of the company’sCVL-231 antipsychoticdrug.\nThe CVL-231 treatment seeks to reduce the release of dopamine in patients without directly targeting dopamine receptors. It does this by manipulating the activation of M4 receptors in the brain.\nOver a six-week trial period, subjects were administered either a once- or twice-daily dosage of CVL-231, or a placebo. At the end of the trial, the company noticed a statistically significant reduction of “psychotic activity” in the subjects taking CVL-231 as compared to those taking the placebo.\nAlso of note is the optimistic information regarding side effects. According to the company’s press release, the drug was well tolerated. Side effects, including headaches and heart rate and blood pressure increases, were relatively stable between both those taking CVL-231 and those taking the placebo.\nCERE Stock Sees Gigantic Gains After Posting Trial Results\nThe results of this trial are very positive for the company. Chief Scientific Officer of Cerevel, Dr. John Renger, commented on the results, reaffirming the company’s belief that it is on the right track:\n\n “We are extremely encouraged with these results, which we believe support our hypothesis that a targeted muscarinic therapy that is highly selective for M4 receptors could deliver clinically meaningful benefit in the treatment of schizophrenia.”\n\nThe next step, according to the company, is moving the drug into more robust trials.\nAs a result of the positive press release, CERE stock is flying high today. In fact, the stock is more than doubling in value, rocketing nearly 125% on today’s trading session. Trading volume is up far above the average; over 76 million shares of CERE stock are swapping hands, against the 300,000 daily average.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5076671,"gmtCreate":1625022767862,"gmtModify":1663230319839,"authorId":3581244873474125,"author":{"id":3581244873474125,"idStr":"3581244873474125","authorId":3581244873474125,"name":"US_watchlist","avatar":"https://static.tigerbbs.com/c45e6bbe1cefb0fecde067a20b3c788f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153668518,"type":1,"supId":0,"prevId":0,"content":"<u>great</u>","text":"<u>great</u>","html":"<u>great</u>"}],"langContent":"EN"},{"id":153668022,"gmtCreate":1625022129066,"gmtModify":1703850339516,"author":{"id":"3569880697294695","authorId":"3569880697294695","name":"Catherine321","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3569880697294695","authorIdStr":"3569880697294695"},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153668022","repostId":1114123601,"repostType":4,"repost":{"id":"1114123601","pubTimestamp":1625021346,"share":"https://ttm.financial/m/news/1114123601?lang=&edition=fundamental","pubTime":"2021-06-30 10:49","market":"us","language":"en","title":"CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing","url":"https://stock-news.laohu8.com/highlight/detail?id=1114123601","media":"investorplace","summary":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a bre","content":"<p><b>Cerevel Therapeutics</b>(NASDAQ:<b><u>CERE</u></b>) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing the start of the next phase, a hopeful sign for getting it to market. Investors are taking notice of the 125% gain for CERE stock.</p>\n<p>Cambridge-based Cerevel Therapeutics has been tackling schizophrenia treatment recently, and its newest trial results are showing that it is heading in the right direction. The results come from the testing of the company’sCVL-231 antipsychoticdrug.</p>\n<p>The CVL-231 treatment seeks to reduce the release of dopamine in patients without directly targeting dopamine receptors. It does this by manipulating the activation of M4 receptors in the brain.</p>\n<p>Over a six-week trial period, subjects were administered either a once- or twice-daily dosage of CVL-231, or a placebo. At the end of the trial, the company noticed a statistically significant reduction of “psychotic activity” in the subjects taking CVL-231 as compared to those taking the placebo.</p>\n<p>Also of note is the optimistic information regarding side effects. According to the company’s press release, the drug was well tolerated. Side effects, including headaches and heart rate and blood pressure increases, were relatively stable between both those taking CVL-231 and those taking the placebo.</p>\n<p>CERE Stock Sees Gigantic Gains After Posting Trial Results</p>\n<p>The results of this trial are very positive for the company. Chief Scientific Officer of Cerevel, Dr. John Renger, commented on the results, reaffirming the company’s belief that it is on the right track:</p>\n<blockquote>\n “We are extremely encouraged with these results, which we believe support our hypothesis that a targeted muscarinic therapy that is highly selective for M4 receptors could deliver clinically meaningful benefit in the treatment of schizophrenia.”\n</blockquote>\n<p>The next step, according to the company, is moving the drug into more robust trials.</p>\n<p>As a result of the positive press release, CERE stock is flying high today. In fact, the stock is more than doubling in value, rocketing nearly 125% on today’s trading session. Trading volume is up far above the average; over 76 million shares of CERE stock are swapping hands, against the 300,000 daily average.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of ...</p>\n\n<a href=\"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CERE":"Cerevel Therapeutics Holdings, Inc."},"source_url":"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114123601","content_text":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing the start of the next phase, a hopeful sign for getting it to market. Investors are taking notice of the 125% gain for CERE stock.\nCambridge-based Cerevel Therapeutics has been tackling schizophrenia treatment recently, and its newest trial results are showing that it is heading in the right direction. The results come from the testing of the company’sCVL-231 antipsychoticdrug.\nThe CVL-231 treatment seeks to reduce the release of dopamine in patients without directly targeting dopamine receptors. It does this by manipulating the activation of M4 receptors in the brain.\nOver a six-week trial period, subjects were administered either a once- or twice-daily dosage of CVL-231, or a placebo. At the end of the trial, the company noticed a statistically significant reduction of “psychotic activity” in the subjects taking CVL-231 as compared to those taking the placebo.\nAlso of note is the optimistic information regarding side effects. According to the company’s press release, the drug was well tolerated. Side effects, including headaches and heart rate and blood pressure increases, were relatively stable between both those taking CVL-231 and those taking the placebo.\nCERE Stock Sees Gigantic Gains After Posting Trial Results\nThe results of this trial are very positive for the company. Chief Scientific Officer of Cerevel, Dr. John Renger, commented on the results, reaffirming the company’s belief that it is on the right track:\n\n “We are extremely encouraged with these results, which we believe support our hypothesis that a targeted muscarinic therapy that is highly selective for M4 receptors could deliver clinically meaningful benefit in the treatment of schizophrenia.”\n\nThe next step, according to the company, is moving the drug into more robust trials.\nAs a result of the positive press release, CERE stock is flying high today. In fact, the stock is more than doubling in value, rocketing nearly 125% on today’s trading session. Trading volume is up far above the average; over 76 million shares of CERE stock are swapping hands, against the 300,000 daily average.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153661762,"gmtCreate":1625022127656,"gmtModify":1703850338049,"author":{"id":"3575278772806449","authorId":"3575278772806449","name":"Cubercubic","avatar":"https://static.tigerbbs.com/5d46b0e4acd8b6b6e6db6afeabed9ef7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575278772806449","authorIdStr":"3575278772806449"},"htmlText":"To the moon?","listText":"To the moon?","text":"To the moon?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153661762","repostId":1114123601,"repostType":4,"repost":{"id":"1114123601","pubTimestamp":1625021346,"share":"https://ttm.financial/m/news/1114123601?lang=&edition=fundamental","pubTime":"2021-06-30 10:49","market":"us","language":"en","title":"CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing","url":"https://stock-news.laohu8.com/highlight/detail?id=1114123601","media":"investorplace","summary":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a bre","content":"<p><b>Cerevel Therapeutics</b>(NASDAQ:<b><u>CERE</u></b>) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing the start of the next phase, a hopeful sign for getting it to market. Investors are taking notice of the 125% gain for CERE stock.</p>\n<p>Cambridge-based Cerevel Therapeutics has been tackling schizophrenia treatment recently, and its newest trial results are showing that it is heading in the right direction. The results come from the testing of the company’sCVL-231 antipsychoticdrug.</p>\n<p>The CVL-231 treatment seeks to reduce the release of dopamine in patients without directly targeting dopamine receptors. It does this by manipulating the activation of M4 receptors in the brain.</p>\n<p>Over a six-week trial period, subjects were administered either a once- or twice-daily dosage of CVL-231, or a placebo. At the end of the trial, the company noticed a statistically significant reduction of “psychotic activity” in the subjects taking CVL-231 as compared to those taking the placebo.</p>\n<p>Also of note is the optimistic information regarding side effects. According to the company’s press release, the drug was well tolerated. Side effects, including headaches and heart rate and blood pressure increases, were relatively stable between both those taking CVL-231 and those taking the placebo.</p>\n<p>CERE Stock Sees Gigantic Gains After Posting Trial Results</p>\n<p>The results of this trial are very positive for the company. Chief Scientific Officer of Cerevel, Dr. John Renger, commented on the results, reaffirming the company’s belief that it is on the right track:</p>\n<blockquote>\n “We are extremely encouraged with these results, which we believe support our hypothesis that a targeted muscarinic therapy that is highly selective for M4 receptors could deliver clinically meaningful benefit in the treatment of schizophrenia.”\n</blockquote>\n<p>The next step, according to the company, is moving the drug into more robust trials.</p>\n<p>As a result of the positive press release, CERE stock is flying high today. In fact, the stock is more than doubling in value, rocketing nearly 125% on today’s trading session. Trading volume is up far above the average; over 76 million shares of CERE stock are swapping hands, against the 300,000 daily average.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of ...</p>\n\n<a href=\"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CERE":"Cerevel Therapeutics Holdings, Inc."},"source_url":"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114123601","content_text":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing the start of the next phase, a hopeful sign for getting it to market. Investors are taking notice of the 125% gain for CERE stock.\nCambridge-based Cerevel Therapeutics has been tackling schizophrenia treatment recently, and its newest trial results are showing that it is heading in the right direction. The results come from the testing of the company’sCVL-231 antipsychoticdrug.\nThe CVL-231 treatment seeks to reduce the release of dopamine in patients without directly targeting dopamine receptors. It does this by manipulating the activation of M4 receptors in the brain.\nOver a six-week trial period, subjects were administered either a once- or twice-daily dosage of CVL-231, or a placebo. At the end of the trial, the company noticed a statistically significant reduction of “psychotic activity” in the subjects taking CVL-231 as compared to those taking the placebo.\nAlso of note is the optimistic information regarding side effects. According to the company’s press release, the drug was well tolerated. Side effects, including headaches and heart rate and blood pressure increases, were relatively stable between both those taking CVL-231 and those taking the placebo.\nCERE Stock Sees Gigantic Gains After Posting Trial Results\nThe results of this trial are very positive for the company. Chief Scientific Officer of Cerevel, Dr. John Renger, commented on the results, reaffirming the company’s belief that it is on the right track:\n\n “We are extremely encouraged with these results, which we believe support our hypothesis that a targeted muscarinic therapy that is highly selective for M4 receptors could deliver clinically meaningful benefit in the treatment of schizophrenia.”\n\nThe next step, according to the company, is moving the drug into more robust trials.\nAs a result of the positive press release, CERE stock is flying high today. In fact, the stock is more than doubling in value, rocketing nearly 125% on today’s trading session. Trading volume is up far above the average; over 76 million shares of CERE stock are swapping hands, against the 300,000 daily average.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153663133,"gmtCreate":1625022042322,"gmtModify":1703850336248,"author":{"id":"3582366643541036","authorId":"3582366643541036","name":"Bonds","avatar":"https://static.tigerbbs.com/7927febac32666ca13d21b532f0ff6f6","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3582366643541036","authorIdStr":"3582366643541036"},"htmlText":"Hope the rest will be the same&nbsp;","listText":"Hope the rest will be the same&nbsp;","text":"Hope the rest will be the same","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153663133","repostId":1114123601,"repostType":4,"repost":{"id":"1114123601","pubTimestamp":1625021346,"share":"https://ttm.financial/m/news/1114123601?lang=&edition=fundamental","pubTime":"2021-06-30 10:49","market":"us","language":"en","title":"CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing","url":"https://stock-news.laohu8.com/highlight/detail?id=1114123601","media":"investorplace","summary":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a bre","content":"<p><b>Cerevel Therapeutics</b>(NASDAQ:<b><u>CERE</u></b>) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing the start of the next phase, a hopeful sign for getting it to market. Investors are taking notice of the 125% gain for CERE stock.</p>\n<p>Cambridge-based Cerevel Therapeutics has been tackling schizophrenia treatment recently, and its newest trial results are showing that it is heading in the right direction. The results come from the testing of the company’sCVL-231 antipsychoticdrug.</p>\n<p>The CVL-231 treatment seeks to reduce the release of dopamine in patients without directly targeting dopamine receptors. It does this by manipulating the activation of M4 receptors in the brain.</p>\n<p>Over a six-week trial period, subjects were administered either a once- or twice-daily dosage of CVL-231, or a placebo. At the end of the trial, the company noticed a statistically significant reduction of “psychotic activity” in the subjects taking CVL-231 as compared to those taking the placebo.</p>\n<p>Also of note is the optimistic information regarding side effects. According to the company’s press release, the drug was well tolerated. Side effects, including headaches and heart rate and blood pressure increases, were relatively stable between both those taking CVL-231 and those taking the placebo.</p>\n<p>CERE Stock Sees Gigantic Gains After Posting Trial Results</p>\n<p>The results of this trial are very positive for the company. Chief Scientific Officer of Cerevel, Dr. John Renger, commented on the results, reaffirming the company’s belief that it is on the right track:</p>\n<blockquote>\n “We are extremely encouraged with these results, which we believe support our hypothesis that a targeted muscarinic therapy that is highly selective for M4 receptors could deliver clinically meaningful benefit in the treatment of schizophrenia.”\n</blockquote>\n<p>The next step, according to the company, is moving the drug into more robust trials.</p>\n<p>As a result of the positive press release, CERE stock is flying high today. In fact, the stock is more than doubling in value, rocketing nearly 125% on today’s trading session. Trading volume is up far above the average; over 76 million shares of CERE stock are swapping hands, against the 300,000 daily average.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of ...</p>\n\n<a href=\"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CERE":"Cerevel Therapeutics Holdings, Inc."},"source_url":"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114123601","content_text":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing the start of the next phase, a hopeful sign for getting it to market. Investors are taking notice of the 125% gain for CERE stock.\nCambridge-based Cerevel Therapeutics has been tackling schizophrenia treatment recently, and its newest trial results are showing that it is heading in the right direction. The results come from the testing of the company’sCVL-231 antipsychoticdrug.\nThe CVL-231 treatment seeks to reduce the release of dopamine in patients without directly targeting dopamine receptors. It does this by manipulating the activation of M4 receptors in the brain.\nOver a six-week trial period, subjects were administered either a once- or twice-daily dosage of CVL-231, or a placebo. At the end of the trial, the company noticed a statistically significant reduction of “psychotic activity” in the subjects taking CVL-231 as compared to those taking the placebo.\nAlso of note is the optimistic information regarding side effects. According to the company’s press release, the drug was well tolerated. Side effects, including headaches and heart rate and blood pressure increases, were relatively stable between both those taking CVL-231 and those taking the placebo.\nCERE Stock Sees Gigantic Gains After Posting Trial Results\nThe results of this trial are very positive for the company. Chief Scientific Officer of Cerevel, Dr. John Renger, commented on the results, reaffirming the company’s belief that it is on the right track:\n\n “We are extremely encouraged with these results, which we believe support our hypothesis that a targeted muscarinic therapy that is highly selective for M4 receptors could deliver clinically meaningful benefit in the treatment of schizophrenia.”\n\nThe next step, according to the company, is moving the drug into more robust trials.\nAs a result of the positive press release, CERE stock is flying high today. In fact, the stock is more than doubling in value, rocketing nearly 125% on today’s trading session. Trading volume is up far above the average; over 76 million shares of CERE stock are swapping hands, against the 300,000 daily average.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153669600,"gmtCreate":1625022004200,"gmtModify":1703850334937,"author":{"id":"3569880697294695","authorId":"3569880697294695","name":"Catherine321","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3569880697294695","authorIdStr":"3569880697294695"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153669600","repostId":1114123601,"repostType":4,"repost":{"id":"1114123601","pubTimestamp":1625021346,"share":"https://ttm.financial/m/news/1114123601?lang=&edition=fundamental","pubTime":"2021-06-30 10:49","market":"us","language":"en","title":"CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing","url":"https://stock-news.laohu8.com/highlight/detail?id=1114123601","media":"investorplace","summary":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a bre","content":"<p><b>Cerevel Therapeutics</b>(NASDAQ:<b><u>CERE</u></b>) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing the start of the next phase, a hopeful sign for getting it to market. Investors are taking notice of the 125% gain for CERE stock.</p>\n<p>Cambridge-based Cerevel Therapeutics has been tackling schizophrenia treatment recently, and its newest trial results are showing that it is heading in the right direction. The results come from the testing of the company’sCVL-231 antipsychoticdrug.</p>\n<p>The CVL-231 treatment seeks to reduce the release of dopamine in patients without directly targeting dopamine receptors. It does this by manipulating the activation of M4 receptors in the brain.</p>\n<p>Over a six-week trial period, subjects were administered either a once- or twice-daily dosage of CVL-231, or a placebo. At the end of the trial, the company noticed a statistically significant reduction of “psychotic activity” in the subjects taking CVL-231 as compared to those taking the placebo.</p>\n<p>Also of note is the optimistic information regarding side effects. According to the company’s press release, the drug was well tolerated. Side effects, including headaches and heart rate and blood pressure increases, were relatively stable between both those taking CVL-231 and those taking the placebo.</p>\n<p>CERE Stock Sees Gigantic Gains After Posting Trial Results</p>\n<p>The results of this trial are very positive for the company. Chief Scientific Officer of Cerevel, Dr. John Renger, commented on the results, reaffirming the company’s belief that it is on the right track:</p>\n<blockquote>\n “We are extremely encouraged with these results, which we believe support our hypothesis that a targeted muscarinic therapy that is highly selective for M4 receptors could deliver clinically meaningful benefit in the treatment of schizophrenia.”\n</blockquote>\n<p>The next step, according to the company, is moving the drug into more robust trials.</p>\n<p>As a result of the positive press release, CERE stock is flying high today. In fact, the stock is more than doubling in value, rocketing nearly 125% on today’s trading session. Trading volume is up far above the average; over 76 million shares of CERE stock are swapping hands, against the 300,000 daily average.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of ...</p>\n\n<a href=\"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CERE":"Cerevel Therapeutics Holdings, Inc."},"source_url":"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114123601","content_text":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing the start of the next phase, a hopeful sign for getting it to market. Investors are taking notice of the 125% gain for CERE stock.\nCambridge-based Cerevel Therapeutics has been tackling schizophrenia treatment recently, and its newest trial results are showing that it is heading in the right direction. The results come from the testing of the company’sCVL-231 antipsychoticdrug.\nThe CVL-231 treatment seeks to reduce the release of dopamine in patients without directly targeting dopamine receptors. It does this by manipulating the activation of M4 receptors in the brain.\nOver a six-week trial period, subjects were administered either a once- or twice-daily dosage of CVL-231, or a placebo. At the end of the trial, the company noticed a statistically significant reduction of “psychotic activity” in the subjects taking CVL-231 as compared to those taking the placebo.\nAlso of note is the optimistic information regarding side effects. According to the company’s press release, the drug was well tolerated. Side effects, including headaches and heart rate and blood pressure increases, were relatively stable between both those taking CVL-231 and those taking the placebo.\nCERE Stock Sees Gigantic Gains After Posting Trial Results\nThe results of this trial are very positive for the company. Chief Scientific Officer of Cerevel, Dr. John Renger, commented on the results, reaffirming the company’s belief that it is on the right track:\n\n “We are extremely encouraged with these results, which we believe support our hypothesis that a targeted muscarinic therapy that is highly selective for M4 receptors could deliver clinically meaningful benefit in the treatment of schizophrenia.”\n\nThe next step, according to the company, is moving the drug into more robust trials.\nAs a result of the positive press release, CERE stock is flying high today. In fact, the stock is more than doubling in value, rocketing nearly 125% on today’s trading session. Trading volume is up far above the average; over 76 million shares of CERE stock are swapping hands, against the 300,000 daily average.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153669029,"gmtCreate":1625021992961,"gmtModify":1703850333788,"author":{"id":"3585004399691413","authorId":"3585004399691413","name":"HongBoonPing","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585004399691413","authorIdStr":"3585004399691413"},"htmlText":"Ok great","listText":"Ok great","text":"Ok great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153669029","repostId":1114123601,"repostType":4,"repost":{"id":"1114123601","pubTimestamp":1625021346,"share":"https://ttm.financial/m/news/1114123601?lang=&edition=fundamental","pubTime":"2021-06-30 10:49","market":"us","language":"en","title":"CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing","url":"https://stock-news.laohu8.com/highlight/detail?id=1114123601","media":"investorplace","summary":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a bre","content":"<p><b>Cerevel Therapeutics</b>(NASDAQ:<b><u>CERE</u></b>) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing the start of the next phase, a hopeful sign for getting it to market. Investors are taking notice of the 125% gain for CERE stock.</p>\n<p>Cambridge-based Cerevel Therapeutics has been tackling schizophrenia treatment recently, and its newest trial results are showing that it is heading in the right direction. The results come from the testing of the company’sCVL-231 antipsychoticdrug.</p>\n<p>The CVL-231 treatment seeks to reduce the release of dopamine in patients without directly targeting dopamine receptors. It does this by manipulating the activation of M4 receptors in the brain.</p>\n<p>Over a six-week trial period, subjects were administered either a once- or twice-daily dosage of CVL-231, or a placebo. At the end of the trial, the company noticed a statistically significant reduction of “psychotic activity” in the subjects taking CVL-231 as compared to those taking the placebo.</p>\n<p>Also of note is the optimistic information regarding side effects. According to the company’s press release, the drug was well tolerated. Side effects, including headaches and heart rate and blood pressure increases, were relatively stable between both those taking CVL-231 and those taking the placebo.</p>\n<p>CERE Stock Sees Gigantic Gains After Posting Trial Results</p>\n<p>The results of this trial are very positive for the company. Chief Scientific Officer of Cerevel, Dr. John Renger, commented on the results, reaffirming the company’s belief that it is on the right track:</p>\n<blockquote>\n “We are extremely encouraged with these results, which we believe support our hypothesis that a targeted muscarinic therapy that is highly selective for M4 receptors could deliver clinically meaningful benefit in the treatment of schizophrenia.”\n</blockquote>\n<p>The next step, according to the company, is moving the drug into more robust trials.</p>\n<p>As a result of the positive press release, CERE stock is flying high today. In fact, the stock is more than doubling in value, rocketing nearly 125% on today’s trading session. Trading volume is up far above the average; over 76 million shares of CERE stock are swapping hands, against the 300,000 daily average.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of ...</p>\n\n<a href=\"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CERE":"Cerevel Therapeutics Holdings, Inc."},"source_url":"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114123601","content_text":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing the start of the next phase, a hopeful sign for getting it to market. Investors are taking notice of the 125% gain for CERE stock.\nCambridge-based Cerevel Therapeutics has been tackling schizophrenia treatment recently, and its newest trial results are showing that it is heading in the right direction. The results come from the testing of the company’sCVL-231 antipsychoticdrug.\nThe CVL-231 treatment seeks to reduce the release of dopamine in patients without directly targeting dopamine receptors. It does this by manipulating the activation of M4 receptors in the brain.\nOver a six-week trial period, subjects were administered either a once- or twice-daily dosage of CVL-231, or a placebo. At the end of the trial, the company noticed a statistically significant reduction of “psychotic activity” in the subjects taking CVL-231 as compared to those taking the placebo.\nAlso of note is the optimistic information regarding side effects. According to the company’s press release, the drug was well tolerated. Side effects, including headaches and heart rate and blood pressure increases, were relatively stable between both those taking CVL-231 and those taking the placebo.\nCERE Stock Sees Gigantic Gains After Posting Trial Results\nThe results of this trial are very positive for the company. Chief Scientific Officer of Cerevel, Dr. John Renger, commented on the results, reaffirming the company’s belief that it is on the right track:\n\n “We are extremely encouraged with these results, which we believe support our hypothesis that a targeted muscarinic therapy that is highly selective for M4 receptors could deliver clinically meaningful benefit in the treatment of schizophrenia.”\n\nThe next step, according to the company, is moving the drug into more robust trials.\nAs a result of the positive press release, CERE stock is flying high today. In fact, the stock is more than doubling in value, rocketing nearly 125% on today’s trading session. Trading volume is up far above the average; over 76 million shares of CERE stock are swapping hands, against the 300,000 daily average.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153681081,"gmtCreate":1625021516543,"gmtModify":1703850322337,"author":{"id":"3579330323457305","authorId":"3579330323457305","name":"StanWong","avatar":"https://static.tigerbbs.com/e9322e2e8d8a17e2d556393294550ba0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579330323457305","authorIdStr":"3579330323457305"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153681081","repostId":1114123601,"repostType":4,"repost":{"id":"1114123601","pubTimestamp":1625021346,"share":"https://ttm.financial/m/news/1114123601?lang=&edition=fundamental","pubTime":"2021-06-30 10:49","market":"us","language":"en","title":"CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing","url":"https://stock-news.laohu8.com/highlight/detail?id=1114123601","media":"investorplace","summary":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a bre","content":"<p><b>Cerevel Therapeutics</b>(NASDAQ:<b><u>CERE</u></b>) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing the start of the next phase, a hopeful sign for getting it to market. Investors are taking notice of the 125% gain for CERE stock.</p>\n<p>Cambridge-based Cerevel Therapeutics has been tackling schizophrenia treatment recently, and its newest trial results are showing that it is heading in the right direction. The results come from the testing of the company’sCVL-231 antipsychoticdrug.</p>\n<p>The CVL-231 treatment seeks to reduce the release of dopamine in patients without directly targeting dopamine receptors. It does this by manipulating the activation of M4 receptors in the brain.</p>\n<p>Over a six-week trial period, subjects were administered either a once- or twice-daily dosage of CVL-231, or a placebo. At the end of the trial, the company noticed a statistically significant reduction of “psychotic activity” in the subjects taking CVL-231 as compared to those taking the placebo.</p>\n<p>Also of note is the optimistic information regarding side effects. According to the company’s press release, the drug was well tolerated. Side effects, including headaches and heart rate and blood pressure increases, were relatively stable between both those taking CVL-231 and those taking the placebo.</p>\n<p>CERE Stock Sees Gigantic Gains After Posting Trial Results</p>\n<p>The results of this trial are very positive for the company. Chief Scientific Officer of Cerevel, Dr. John Renger, commented on the results, reaffirming the company’s belief that it is on the right track:</p>\n<blockquote>\n “We are extremely encouraged with these results, which we believe support our hypothesis that a targeted muscarinic therapy that is highly selective for M4 receptors could deliver clinically meaningful benefit in the treatment of schizophrenia.”\n</blockquote>\n<p>The next step, according to the company, is moving the drug into more robust trials.</p>\n<p>As a result of the positive press release, CERE stock is flying high today. In fact, the stock is more than doubling in value, rocketing nearly 125% on today’s trading session. Trading volume is up far above the average; over 76 million shares of CERE stock are swapping hands, against the 300,000 daily average.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of ...</p>\n\n<a href=\"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CERE":"Cerevel Therapeutics Holdings, Inc."},"source_url":"https://investorplace.com/2021/06/cere-stock-the-huge-news-that-has-cerevel-therapeutics-skyrocketing/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114123601","content_text":"Cerevel Therapeutics(NASDAQ:CERE) stock is up monumentally, thanks to some positive results in a breakthrough trial. It appears that a therapy by the company developed for the treatment of schizophrenia is nearing the start of the next phase, a hopeful sign for getting it to market. Investors are taking notice of the 125% gain for CERE stock.\nCambridge-based Cerevel Therapeutics has been tackling schizophrenia treatment recently, and its newest trial results are showing that it is heading in the right direction. The results come from the testing of the company’sCVL-231 antipsychoticdrug.\nThe CVL-231 treatment seeks to reduce the release of dopamine in patients without directly targeting dopamine receptors. It does this by manipulating the activation of M4 receptors in the brain.\nOver a six-week trial period, subjects were administered either a once- or twice-daily dosage of CVL-231, or a placebo. At the end of the trial, the company noticed a statistically significant reduction of “psychotic activity” in the subjects taking CVL-231 as compared to those taking the placebo.\nAlso of note is the optimistic information regarding side effects. According to the company’s press release, the drug was well tolerated. Side effects, including headaches and heart rate and blood pressure increases, were relatively stable between both those taking CVL-231 and those taking the placebo.\nCERE Stock Sees Gigantic Gains After Posting Trial Results\nThe results of this trial are very positive for the company. Chief Scientific Officer of Cerevel, Dr. John Renger, commented on the results, reaffirming the company’s belief that it is on the right track:\n\n “We are extremely encouraged with these results, which we believe support our hypothesis that a targeted muscarinic therapy that is highly selective for M4 receptors could deliver clinically meaningful benefit in the treatment of schizophrenia.”\n\nThe next step, according to the company, is moving the drug into more robust trials.\nAs a result of the positive press release, CERE stock is flying high today. In fact, the stock is more than doubling in value, rocketing nearly 125% on today’s trading session. Trading volume is up far above the average; over 76 million shares of CERE stock are swapping hands, against the 300,000 daily average.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":113,"commentSize":11,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}